Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -b receptor complex and is involved in vascular development and remodelling. Quantification of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to have prognostic significance in selected neoplasias. In addition, the potential usefulness of CD105 in tumor imaging and antiangiogenetic therapy has been well documented utilizing different animal models.
Introduction
The well-established notion that malignant tumors depend on angiogenesis to grow and metastasize (Carmeliet and Jain, 2000) has stimulated great interest on the potential clinical implications of the inhibition of tumor-associated angiogenesis (Brekken et al., 2002; Rajkumar et al., 2002; Scappaticci, 2002) . Accordingly, prompted by the swift progress of basic research in this field, different antiangiogenetic approaches are currently being tested in clinical trials in cancer patients Scappaticci, 2002) . Aim of these new therapeutic strategies is to induce tumor regression and to inhibit its metastatic spreading by blocking the needs of nutrients and oxygen exchange of neoplastic cells. Advantages of antiangiogenetic cancer treatment consist in circumventing the main problems associated with conventional cancer therapies including: applicability to neoplasias of different histotype, drug resistance, toxicity and limited accessibility of drugs to their cellular targets (Brekken et al., 2002; Scappaticci, 2002) .
Besides strategies aiming to inhibit the activity of proangiogenetic agents or treatments with angiogenetic inhibitors, an intriguing therapeutic approach relies on the selective targeting of proliferating endothelial cells within tumor-associated blood vessels. However, neither specific markers of endothelial cell proliferation nor molecules able to discriminate between endothelial cells from blood vessels within transformed and normal tissues have been identified yet. Nevertheless, it has long been established that endothelial cells of the tumor vasculature undergo a very more rapid proliferation than quiescent endothelial cells in the vasculature of normal tissues (Denekamp, 1990) ; thus, molecules overexpressed on actively proliferating endothelial cells represent useful targets for antiangiogenetic therapeutic approaches.
In this review, we will summarize the complex of experimental evidences suggesting a crucial role of endoglin (CD105) in physiologic angiogenesis and pointing to CD105 as an attractive vascular endothelial target to design innovative bioimmunotherapeutic strategies for human malignancies.
Structural and functional features
CD105 is a disulfide-linked homodimeric cell membrane glycoprotein of 180 kDa (Gougos and Letarte, 1988) . The two known isoforms of CD105, L and S, differ from each other for the cytoplasmic tail (Gougos and Letarte, 1990; Bello´n et al., 1993) . Both isoforms are constitutively phosphorylated (Lastres et al., 1994) , and L-CD105, the longer variant with a cytoplasmic tail of 47 amino-acid residues, is predominantly expressed on endothelial cells (Cheifetz et al., 1992) .
In humans, CD105 gene is located on chromosome 9q34-qter (Fernandez-Ruiz et al., 1993) and it is arranged into 14 exons (McAllister et al., 1995) . The promoter region of CD105 gene was cloned and characterized (Rı´us et al., 1998; Graulich et al., 1999; Botella et al., 2002) and it showed inducibility in the presence of transforming growth factor (TGF) -b1 (Rı´us et al., 1998) . CD105 promoter has a stronger activity in endothelial cells compared to other cell types such as epithelial cells . This marked tissue-specificity of CD105 transcription is likely regulated by distinct mechanisms acting on the 5 0 region of the promoter .
Mutations in CD105 gene are associated with hereditary hemorrhagic telangiectasia (HHT) type 1 (HHT1), an autosomal-dominant inherited vascular disorder characterized by arteriovenous malformations and frequent bleedings (McAllister et al., 1994; van den Driesche et al., 2003) . The clinical symptoms of the disease are heterogeneous among different families and among members of a single family. Experimental evidences in mice lacking CD105 suggest that CD105 haploinsufficiency, combined with the effects of genes that regulate TGF-b1 expression, might affect HHT1 severity (Bourdeau et al., 1999 .
CD105 is a component of the receptor complex of TGF-b (Cheifetz et al., 1992; Barbara et al., 1999) , a pleiotropic cytokine that modulates angiogenesis by the regulation of different cellular functions including proliferation, differentiation and migration (Blobe et al., 2000; Zhu and Burgess, 2001 ). CD105 binds several components of the TGF-b superfamily including activin-A, BMP-7 and BMP-2 (Barbara et al., 1999) . In particular, it binds TGF-b1 and -b3 with high affinity by associating with the TGF-b type II receptor (Cheifetz et al., 1992; Letamendı´a et al., 1998b; Barbara et al., 1999) . Interestingly, binding of TGF-b to CD105 reduces the levels of CD105 phosphorylation (Lastres et al., 1994) . The overexpression of CD105 antagonizes several cellular responses to TGF-b1, while its downregulation potentiates cellular responses to TGF-b1 Letamendı´a et al., 1998b; Li et al., 2000b; Ma et al., 2000; Diez-Marques et al., 2002) .
In this regard, the inhibition of CD105 expression on human umbilical vein endothelial cells (HUVEC) by an antisense approach, enhanced the ability of TGF-b1 to suppress their growth, migration and capacity to form capillary tubes (Li et al., 2000b) . Recently, it has been demonstrated that CD105 affects cellular responses to TGF-b by interacting through its extracellular and cytoplasmic domains with the TGF-b signalling receptors types I and II .
Expression
CD105 expression is mainly restricted to vascular endothelial cells on which high levels of protein are detectable (Gougos and Letarte, 1988; Wang et al., 1993; Burrows et al., 1995; Miller et al., 1999; Fonsatti et al., 2001) . Furthermore, CD105 is weakly expressed on hematopoietic progenitor cells (Cho et al., 2001; Pierelli et al., 2001) , fibroblasts (Gougos and Letarte, 1988; Robledo et al., 1996) , stromal (Rokhlin et al., 1995) and vascular smooth muscle cells (Adam et al., 1998) , macrophages (Lastres et al., 1992; O'Connell et al., 1992) and mesangial cells (Diez-Marques et al., 2002) .
CD105 is absent or scarcely expressed on lymphatic endothelial cells isolated from human skin (Hirakawa et al., 2003) ; instead, high levels of CD105 are detectable on human microvascular endothelium, where it is associated with betaglycan (Wong et al., 2000) , an additional component of the TGF-b receptor complex.
In solid malignancies, CD105 is almost exclusively expressed on endothelial cells of both peri-and intratumoral blood vessels and on tumor stromal components (Wang et al., 1993; Burrows et al., 1995; Fonsatti et al., 2001 ; Figure 1 ). Furthermore, small and likely immature tumor vessels are mainly stained Wikstrom et al., 2002) . Although at low frequency, CD105 expression was found in the cytoplasm of neoplastic cells in meningiomas ; Figure 1 ), in sarcomas of different histotype ; Figure 1 ), in the ovary (Henriksen et al., 1995) and breast carcinomas (Fonsatti et al., 2000) . As far as melanoma, CD105 was detected in 25% (3/ 12) and 34% (10/29) of primary and metastatic lesions, respectively; the majority of the metastatic cells displayed a variable degree of CD105 expression. Furthermore, endothelial cells, but not smooth muscle cells, of blood vessels within all lesions investigated were strongly stained by the anti-CD105 mAb MAEND3 (Altomonte et al., 1996) .
Concerning hemopoietic tumors, CD105 is expressed on pro-B and pre-B leukemic cell lines (Gougos and Letarte, 1988; O'Connell et al., 1992; Rokhlin et al., 1995) , on stem cell-derived malignancies such as refractory anemia with excess of blasts and blast crisis of chronic myelogenous leukemia (Haruta and Seon, 1986; Lo Pardo et al., 1997) . In different subtypes of acute leukemias, CD105 was invariably detected on the most immature cellular subtypes but not on more differentiated ones .
Functional implications in angiogenesis, vascular development and cancer progression
Initial evidences suggesting the involvement of CD105 in angiogenesis and pointing to CD105 as a powerful candidate for vascular targeting derived from the observations that it is overexpressed on proliferating endothelial cells both in vitro and in vivo Burrows et al., 1995; Miller et al., 1999; Fonsatti et al., 2000) . In this respect, very high levels of CD105 expression on HUVEC were strictly associated with protein, RNA and DNA levels consistent with cellular activation and proliferation (Burrows et al., 1995) . In agreement with these findings, a significant inverse correlation was found between levels of CD105 expression and HUVEC density in culture (Fonsatti et al., 2000) , while a direct correlation was detected with the expression of cyclin A and Ki-67 in tumor endothelial cells (Miller et al., 1999) . Furthermore, it was found that selected anti-CD105 mAb stained with high intensity vascular endothelial cells in tissues undergoing active angiogenesis, whereas no or weak staining for CD105 was detected in blood vessels within normal tissues (Wang et al., 1993; Krupinski et al., 1994; Burrows et al., 1995; Miller et al., 1999; Schimming and Marme, 2002) .
In agreement with the notion that angiogenesis is positively regulated by hypoxia (Choi et al., 2003) and that CD105 is overexpressed in the neovasculature of angiogenetic tissues (Krupinski et al., 1994; Burrows et al., 1995; Conley et al., 2000) , it was demonstrated that surface protein, transcript and promoter activity levels of CD105 are moderately upregulated by hypoxia via the hypoxia inducible factor (HIF)-1 complex, and that hypoxic conditions and TGF-b1 cooperate to induce the expression of CD105 at transcriptional level .
As detected by Northern blot and oligonucleotide microarray analyses, CD105 expression is upregulated on HUVEC infected with a recombinant adenovirus carrying a constitutively active form of activin receptorlike kinase (ALK)-1 (Ota et al., 2002) . ALK-1 is a type I TGF-b receptor whose haploinsufficiency is associated with HHT type 2 (Abdalla et al., 2000) . Since mutations both in ALK-1 and in CD105 genes are associated with HHTs, and both CD105-and ALK-1-null mice died of defective vascular development during gestation Urness et al., 2000) , it has been suggested that ALK-1 and CD105 may cooperatively regulate the binding of TGF-b superfamily ligands and that both molecules are involved in maintaining vessel wall integrity (Abdalla et al., 2000; Ota et al., 2002) .
As reported for ALK-1 (Roelen et al, 1997) , the pattern of CD105 expression in early mouse development is associated with vasculogenesis and angiogenesis. In mouse embryogenesis, CD105 expression was detected between 7.5 and 8.5 days of gestation on endothelial cells of yolk sac, dorsal aorta and primitive heart tube, and on endothelial cells throughout the developing vasculature from 9.5 to 13.5 days (Jonker and Arthur, 2002) . In human embryogenesis, CD105 was exclusively expressed on vascular endothelium at 4-8 weeks of gestation and transiently overexpressed during heart septation and valve formation (Qu et al., 1998) .
Supporting the functional involvement of CD105 in angiogenesis, the anti-CD105 mAb TEC-11 significantly inhibited the proliferation of cultured human microvascular and macrovascular endothelial cells; in addition, masking of CD105 by mAb TEC-11 reduced the production of urokinase-type plasminogen activator by HUVEC (Maier et al., 1997) .
Several studies have defined the role of CD105 as a powerful marker to quantify intratumoral microvessel density (IMVD) in solid and hematopoietic tumors including breast (Kumar et al., 1999) , prostate (Wikstrom et al., 2002) , cervical (Brewer et al., 2000) , colorectal (Akagi et al., 2002) and non-small cell lung cancer (NSCLC) (Tanaka et al., 2001) , and in multiple myeloma (Pruneri et al., 2002) and hairy cell leukemia (Pruneri et al., 2003) . Moreover, in NSCLC, increased levels of angiopoietin-2 (an antagonist of angiopoietin-1) significantly correlated with higher IMVD assessed by immunohistochemical staining against CD105. Interestingly, in angiopoietin-2-positive NSCLC, CD105-IMVD was elevated when levels of vascular endothelial growth factor (VEGF) expression were high (Tanaka et al., 2002) . Additionally, a retrospective study on 237 consecutive patients affected by NSCLC (stages I-IIIa), demonstrated a higher apoptotic index in cancer patients with lower IMVD as assessed by the staining for CD105 (Tanaka et al., 2003 ).
An increment in microvessel density, as determined by the staining for CD105, was found during the progressive stages of colorectal carcinogenesis, suggesting that the assessment of neovascularization, utilizing CD105 as a marker, might represent a predictor of colorectal cancer development (Akagi et al., 2002) . Further evidence that CD105 is involved in tumor progression is provided by the finding that it represents a differentiation marker of human choriocarcinoma cells; in fact, treatment of choriocarcinoma cells with methotrexate, a folic acid antagonist, induced their morphological differentiation into nonproliferating syncytiotrophoblast-like cells, in association with increased levels of CD105 expression (Letamendı´a et al., 1998a) .
Recently, CD105 has been reported to play a role in the regulation of adhesion, motility and invasion of normal and transformed human prostate cells (Liu et al., 2002) . Consistently, CD105 showed focal localization to normal prostate cell contacts (Liu et al., 2002) ; unique among 4000 genes evaluated, CD105 was upregulated during detachment of metastatic prostate cells (Jovanovic et al., 2001) . In addition, transfection of human prostate cancer cells with a cDNA encoding for L-or S-CD105 decreased their detachment, migration and invasion, suggesting that loss of CD105 on prostate cancer cells favors the development of metastasis (Liu et al., 2002) .
Clinical implications
Quantification of tumor microvessel density, as determined by immunohistochemical staining for CD105, is a significant indicator of poor prognosis in patients with selected solid neoplasias including NSCLC (Tanaka et al., 2001) , cervical cancer (Brewer et al., 2000) , prostate cancer with Gleason score 5-7 (Wikstrom et al., 2002) and breast carcinoma (Kumar et al., 1999; Dales et al., 2003) . Moreover, a weaker intensity of staining for CD105 was observed in T1 compared to T2, T3 or T4 squamous cell carcinomas of the oral cavity (Schimming and Marme, 2002) .
Supporting the diagnostic potential of CD105 in cancer, radiolabelled anti-CD105 mAb efficiently imaged human melanoma xenografts in C57BL/6 mice (Bredow et al., 2000) and spontaneous mammary adenocarcinomas in a canine model (Fonsatti et al., 2000) . These findings suggest that targeting of CD105 by radiolabelled mAb is a promising and safe procedure to image solid malignancies, regardless of their histological origin and independently from CD105 expression on malignant cells.
Targeting of CD105 for the treatment of solid tumors has been experimentally validated in mice; in fact, radiolabelled or immunotoxin-conjugated anti-CD105 mAb demonstrated a high antitumor efficacy in severe combined immunodeficiency (SCID) mice bearing human breast carcinomas, likely mediated by the inhibition of tumor-associated angiogenesis, and/or by the destruction of tumor-associated vasculature (Seon et al., 1997; Matsuno et al., 1999; Tabata et al., 1999) . Successively, the ability of unconjugated anti-CD105 mAb to suppress tumor growth was investigated in human skin/SCID mouse chimeras bearing MCF-7 tumor cells (Takahashi et al., 2001a) . To this end, human breast cancer cells were inoculated into the grafted human skin, which contained human blood vessels as well as mouse blood vessels. The results indicated that the combination of anti-CD105 mAb and cyclophosphamide had synergistic antitumor efficacy and completely suppressed established tumors in some chimeras (Takahashi et al., 2001a) ; noteworthy, anti-CD105 mAb effectively suppressed human vessels, while they had only a weak suppressive activity on the growth of murine vessels of large established tumors (Takahashi et al., 2001a) .
A bispecific single-chain diabody directed to the adenovirus fiber knob domain and to CD105 was shown to be effective in enhancing selective adenovirus transduction in HUVEC, thus sustaining the feasibility of CD105 protein as target for therapeutic gene transfer in endothelial cells (Nettelbeck et al., 2001) . In addition, it has been demonstrated that a vector constructed with the CD105 promoter can be efficiently utilized to deliver gene expression specifically to endothelial cells of mouse blood vessels (Velasco et al., 2001) . Moreover, human CD105 promoter fragments were utilized to drive complement regulatory proteins (CRPs) expression in pigs, generating a strong CRP expression in the small vessels of heart, kidney and lung, but not in the large vessels (Cowan et al., 2003) . These observations further support the preferential expression of CD105 on endothelial cells of the microvasculature.
Another intriguing strategy of CD105 targeting for antiangiogenetic treatment of cancer might derive by the use of conditionally replicating adenoviruses (CRAD). It has been reported that CRAD, obtained by utilizing Flk-1 and CD105 regulatory elements, can be transcriptionally targeted towards proliferating endothelial cells with high specificity and that they are effective in killing HUVEC (Savontaus et al., 2002) .
Soluble form (sCD105)
Up-coming evidences demonstrate that compared to healthy subjects, higher levels of a circulating form of sCD105 are detectable in sera and/or plasma of patients with solid (Li et al., 2000b; Takahashi et al., 2001b) and hematological neoplasias (Calabro`et al., 2003) . Although preliminary, these findings indicate that sCD105 might play a role in cancer progression.
The highest amounts of circulating sCD105 were found in breast and colorectal cancer patients with metastatic disease and increased levels of sCD105 were detected in serum of patients who did not receive chemotherapy (Takahashi et al., 2001b) . These data suggest that monitoring of sCD105 may identify early signs of metastasis and of cancer relapse in long-term follow-up of patients with solid neoplasias and that circulating sCD105 might represent a surrogate marker of angiogenetic activity (Li et al., 2000a; Takahashi et al., 2001b) .
Concerning myeloid hematopoietic malignancies, elevated levels of sCD105 were detected both in acute myeloid leukemia and in chronic myeloproliferative disorders (Calabro`et al., 2003) . Noteworthy, very low levels of sCD105, and an inverse correlation between levels of sCD105 and those of soluble TGF-b1 (sTGFb1), were found in essential thrombocythemia (ET) patients with a history of thrombotic complications. Instead, high levels of sCD105 and a direct correlation between levels of sCD105 and those of sTGF-b1 were detected in ET patients without thrombotic complications. Even if these observations were obtained from a small number of subjects, they suggested that circulating sCD105 might affect the bioactivity and bioavailability of sTGF-b1 in selected myeloid malignancies (Calabroè t al., 2003) .
Future directions
Compelling evidences support the notion that CD105 plays a key role in angiogenesis and that CD105 is an optimal molecular target to set up new diagnostic and bioimmunotherapeutic approaches for human malignancies. However, detection of a variable degree of CD105 expression on the microvasculature of normal tissues has raised concerns about the feasibility of therapeutic applications of anti-CD105 mAb in cancer patients due to potential side effects (Balza et al., 2001) . Nevertheless, it has been reasonably pointed out that most of the therapeutic mAb that are being effectively utilized in the clinic for cancer treatment are not tumorspecific (Seon, 2002) . Thus, the encouraging results so far achieved through the targeting of CD105 in preclinical models warrant additional efforts to identify the most appropriate therapeutic setting(s) to utilize CD105 in cancer diagnosis and treatment. 
